The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
NEW YORK – Roche will share with regulators data from a Phase III trial of its KRAS G12C inhibitor divarasib, showing its ability to keep lung cancer patients alive longer without progression compared ...
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...
The program will help make genetic counselors available to any provider across different medical specialties in Tennessee and ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results